Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/780366

Contents of this Issue

Navigation

Page 5 of 47

4 Clinical OMICs January/February 2017 www.clinicalomics.com News that work in cell lines and in mouse models end up doing very well in human studies and sometimes they don't, so I think it's a good first step." Dr. Korde also points out there are other forms of treatment for breast cancer, and some, such HER2 tar- geted therapies, have proven to be very successful. "I think that to some degree we are a little bit behind other cancers—there are other cancers that really do have very strong target driv- ers, whereas in breast cancer other than HER2 we haven't really found that," Dr. Korde tells ClinicalOMICs. Before bringing this combination to the clinic, the group has a few steps to complete. This means the group won't move to test the raloxifene and cabozantibib combination in humans right away. Instead, they plan to see if it can prevent treatment resistance in xenografts, or tissue from human tumors transplanted in mice. The team also hopes to find more effective drug combinations for breast cancer by testing pairs of anti-tumor agents and drugs for other conditions such as high blood pressure and diabetes. Breast cancer is not the only dis- ease the group hopes to address. It is also applying these techniques to investigate treatment for Alzheimer 's disease, which, according to Dr. Aloy, is a much more difficult task since it involves restoring function in cells rather than simply killing them. (continued from previous page) New Guidelines on Genomic Data Sharing Could be Key to Success of Precision Medicine The American College of Medical Genetics and Genomics (ACMG) recently released a new position statement that tackles the incredibly complex problem of the lack of sharing of genomic testing data. In the new position statement, which was published recently on the ACMG's website under the title "Laboratory and Clinical Genomic Data Sharing is Crucial to Improving Genetic Health Care," the group states that "In order to ensure that patients receive the most informed care as possible, ACMG advo- cates for extensive sharing of laboratory and clinical data derived from individ- uals who have undergone genomic testing. Informa- tion that informs healthcare service delivery should nei- ther be treated as intellectual property nor as a trade secret when other patients may benefit from the knowledge being widely available." The ACMG's new position statement looks to address long-standing ques- tions such as: how can a single provider, laboratory, medical center, or even state possess sufficient knowledge about genetic conditions to deliver the best care possible for patients in need of care? How can we harness the massive amounts of genetic data that are currently being produced to improve patient care, con- tinue to improve critical genetic testing and further the promise of personalized medicine? "The only way that the medical community is going to be able to make sense of the massive amount of genetic information that is now being generated is through broad and responsible sharing among researchers, clinical laboratories, and the clinic," explained co-author of the new ACMG Position Statement James Evans, M.D., Ph.D., professor of genetics and medicine at The University of North Caro- lina. "If we do it in the way that the ACMG statement lays out, genomic medicine can be harnessed to benefit the health of all." The ACMG believes that in order for data sharing to be done in a way that doesn't result in the compromise of privacy for patients and providers, systems are required that: ensure the security of databases, whether centralized or fed- erated; guarantee the confidentiality of patient and family medical information; and provide transparency in the documentation of data sharing transactions. Institute for Research in Biomedicine (IRB) DrAfter123 / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017